CD8/CD28 contributed to the activation of a CD28-deficient T cell leukemia line on antibody-mediated crosslinking.52 These early CD8-based chimeric stimulatory receptors have not been tested in tumor immunotherapy applications but provided essential knowledge of key stimulatory domains in T cells and lay the foundation for the development of CARs. This evidence concerns the gene CD8A and neoplasm.